Alternative administration of camptothecin analogues

Annals of the New York Academy of Sciences

Volumn 922, Issue , 2000, Pages 237-246

  Verschraegen, C F ^a,d   Jaeckle, K ^b   Giovanella, B ^a   Knight, V ^a   Gilbert, B E ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Stehlin Found for Cancer Research   (United States)

^d Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; IRINOTECAN; LIPOSOME; RUBITECAN; TOPOTECAN;

AEROSOL; ANEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG STRUCTURE; ENTEROHEPATIC CIRCULATION; FEVER; HUMAN; NEUTROPENIA; NONHUMAN; PAIN; VOMITING;

EMESIS;

EID: 0034502538     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb07042.x     Document Type: Conference Paper

References (51)

1. Pharmacodynamics of topoisomerase I inhibition. Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan
2. DNA topoisomerase I-targarted chemotherapy of human color cancer in xenografts
3. Topoisomerase I inhibitors: Review and update
4. Topoisomerase-I inhibitors in gynaecologic tumours
5. Topoisomerase I inhibitors in gynecologic cancer
6. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and a relation to antitum or activity
7. Spectroscopic and biochemical characterisation of self-aggregates formed by antitumor drugs of the camptothecin family: Their possible role in the unique mode of drug action
8. Modulation in kinetics of lactone ring hydrolysis of camptothecins upon interaction with topoisomerase I cleavage sites on DNA
9. Comparative molecular field anaylsis and molecular modeling studies of 20-(S)-camptothecin analogs as inhibitors of DNA topoisomerase I and anticancer/antitumor agents
10. Molecular, cellular, and clinical aspects of the pharmacology of 20(S) camptothecin and its derivatives
11. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH
12. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor
13. Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity
14. Phase II study of camptothecin in the treatment of advanced gastrointestinal cancer
15. An overview of the clinical pharmacology of topotecan
16. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11
17. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11
18. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms
19. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea
20. Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts
21. Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks
22. Topoisomerase-I inhibitors in gynecologic tumors
23. New DNA topoisomerase I inhibitor (TI), BNPI 1100, induces cytotoxicity through a dual mechanism in HCT-8 human ileocecal carcinoma cells
24. Lipid-complexed camptothecin: Formulation and initial biodistribution and antitumor activity studies
25. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo
26. Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion
27. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice
28. A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer
29. Clinical pharmaco-kinetics of topotecan
30. Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure
31. Pulmonary delivery of beclomethasone liposome aerosol in volunteers. Tolerance & safety
32. High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection
33. Aerosolized amphotericin B-liposomes for treatment of systemic Candida infections in mice
34. Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice
35. Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice
36. 9 Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenograft and pulmonary cancr metastases in mice
37. Feasibility, phase I and pharmacological study of aerosolized liposomal 9 nitro-(20S)-camptothecin (L9NC) in patients with advanced malignancies in the lungs
38. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates
39. Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies
40. Pharmacologic approaches to the treatment of meningeal malignancy
41. Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study
42. A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid
43. Intrathecal administration of topotecan in nonhuman primates
44. A phase I study of intrathecal topotecan
45. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors
46. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates
47. Phase I and pharmacokinetic study of intraperitoneal topotecan
48. Phase I and pharmacokinetic study of intraperitoneal topotecan
49. Pharmacokinetics of intraperitoneal 9-amincamptothecin or topotecan in phase I trials
50. Oral versus intraperitoneal administration of irinotecan in the treatment of human neuroblastoma in nude mice
51. Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice